Celldex Therapeutics Inc. | Small-cap | Healthcare
$26.77
-2.80%
| Celldex Therapeutics Stock Comparison:
Celldex Therapeutics vs VertexCelldex Therapeutics vs AlnylamCelldex Therapeutics vs Vera TherapeuticsCelldex Therapeutics vs ViridianCelldex Therapeutics vs AbCellera BiologicsCelldex Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 695.0K
Operating Income -62.7M -9,027.19%
Net Income -53.8M -7,740.43%
EPS (Diluted) $-0.81

Balance Sheet Metrics

Total Assets 739.5M
Total Liabilities 36.5M
Shareholders Equity 703.0M
Debt to Equity 0.05

Cash Flow Metrics

Operating Cash Flow -45.2M
Free Cash Flow -54.6M

Revenue & Profitability Trend

Celldex Therapeutics Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue i 7.0M 6.9M 2.4M 4.7M 7.4M
Cost of Goods Sold i - - - - -
Gross Profit i - - - - -
Gross Margin % i 0.0% 0.0% 0.0% 0.0% 0.0%
Operating Expenses
Research & Development i 163.6M 118.0M 82.3M 53.3M 42.5M
Selling, General & Administrative i 38.5M 30.9M 27.2M 20.5M 14.5M
Other Operating Expenses i - - - - -
Total Operating Expenses i 202.1M 148.9M 109.5M 73.8M 57.0M
Operating Income i -195.1M -142.0M -107.1M -69.1M -49.6M
Operating Margin % i -2,778.9% -2,063.7% -4,543.7% -1,486.7% -668.3%
Non-Operating Items
Interest Income i - - - - -
Interest Expense i - - - - -
Other Non-Operating Income 37.2M 613.0K -5.2M -1.6M -11.4M
Pre-tax Income i -157.9M -141.4M -112.3M -70.7M -60.9M
Income Tax i - 0 0 -227.0K -1.2M
Effective Tax Rate % i 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income i -157.9M -141.4M -112.3M -70.5M -59.8M
Net Margin % i -2,248.8% -2,054.8% -4,765.6% -1,516.0% -805.9%
Key Metrics
EBITDA i -229.1M -139.6M -99.0M -64.5M -34.3M
EPS (Basic) i $-2.45 $-2.92 $-2.40 $-1.64 $-2.02
EPS (Diluted) i $-2.45 $-2.92 $-2.40 $-1.64 $-2.02
Basic Shares Outstanding i 64395000 48449000 46888000 42870000 29640000
Diluted Shares Outstanding i 64395000 48449000 46888000 42870000 29640000

Income Statement Trend

Celldex Therapeutics Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets
Cash & Equivalents i 28.4M 34.8M 29.4M 39.1M 43.8M
Short-term Investments i 696.9M 388.8M 275.5M 369.1M 150.6M
Accounts Receivable i 700.0K 2.6M 347.0K 172.0K 1.8M
Inventory i - - - - -
Other Current Assets 21.2M 5.5M 12.4M 2.4M 1.6M
Total Current Assets i 747.2M 431.7M 317.7M 410.8M 197.8M
Non-Current Assets
Property, Plant & Equipment i 17.3M 14.8M 15.8M 14.1M 14.6M
Goodwill i 27.2M 27.2M 27.2M 27.2M 30.7M
Intangible Assets i 27.2M 27.2M 27.2M 27.2M 30.7M
Long-term Investments - - - - -
Other Non-Current Assets - 107.0K 104.0K 104.0K 41.0K
Total Non-Current Assets i 45.2M 33.9M 35.0M 33.8M 38.0M
Total Assets i 792.3M 465.6M 352.7M 444.7M 235.8M
Liabilities
Current Liabilities
Accounts Payable i 3.3M 3.5M 3.3M 1.2M 1.0M
Short-term Debt i 1.5M 1.6M 1.4M 1.7M 1.3M
Current Portion of Long-term Debt - - - - -
Other Current Liabilities 942.0K 4.0M 990.0K 1.6M 3.4M
Total Current Liabilities i 39.5M 31.1M 18.6M 16.5M 14.2M
Non-Current Liabilities
Long-term Debt i 2.4M 928.0K 2.6M 1.3M 2.2M
Deferred Tax Liabilities i - - - - -
Other Non-Current Liabilities 3.5M 4.4M 5.3M 7.4M 10.1M
Total Non-Current Liabilities i 5.8M 5.3M 7.9M 8.6M 12.3M
Total Liabilities i 45.3M 36.5M 26.5M 25.2M 26.5M
Equity
Common Stock i 66.0K 56.0K 47.0K 47.0K 40.0K
Retained Earnings i -1.6B -1.4B -1.3B -1.1B -1.1B
Treasury Stock i - - - - -
Other Equity - - - - -
Total Shareholders Equity i 747.0M 429.2M 326.2M 419.5M 209.4M
Key Metrics
Total Debt i 3.8M 2.5M 4.0M 3.0M 3.5M
Working Capital i 707.7M 400.6M 299.1M 394.3M 183.6M

Balance Sheet Composition

Celldex Therapeutics Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income i -157.9M -141.4M -112.3M -70.5M -59.8M
Depreciation & Amortization i 3.2M 3.0M 2.9M 3.1M 3.9M
Stock-Based Compensation i 34.2M 23.9M 15.6M 9.0M 3.9M
Working Capital Changes i -13.3M -1.8M 2.6M -2.8M -1.6M
Operating Cash Flow i -133.8M -116.4M -98.1M -63.0M -58.9M
Investing Activities
Capital Expenditures i -1.9M -1.8M -1.8M -1.2M -1.6M
Acquisitions i - - - - -
Investment Purchases i -789.9M -424.6M -189.0M -389.9M -220.3M
Investment Sales i 501.7M 320.6M 280.7M 174.9M 123.6M
Investing Cash Flow i -290.1M -105.8M 89.9M -216.2M -98.2M
Financing Activities
Share Repurchases i - - - - -
Dividends Paid i - - - - -
Debt Issuance i - - 0 0 3.0M
Debt Repayment i - - 0 0 -3.0M
Financing Cash Flow i 432.3M 216.2M 0 269.9M 170.8M
Free Cash Flow i -159.7M -109.1M -105.6M -62.2M -42.0M
Net Change in Cash i 8.4M -5.9M -8.2M -9.2M 13.6M

Cash Flow Trend

Celldex Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -11.03
Forward P/E -8.12
Price to Book 2.66
Price to Sales 300.72
PEG Ratio -0.19

Profitability Ratios

Profit Margin 0.00%
Operating Margin -8,747.53%
Return on Equity -27.18%
Return on Assets -19.08%

Financial Health

Current Ratio 19.67
Debt to Equity 0.46
Beta 1.33

Per Share Data

EPS (TTM) $-3.01
Book Value per Share $9.87
Revenue per Share $0.09

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
cldx 1.7B -11.03 2.66 -27.18% 0.00% 0.46
Vertex 108.0B 29.16 6.12 22.77% 31.86% 8.89
Alnylam 60.2B -209.88 240.24 -257.83% -12.96% 1,093.31
Vera Therapeutics 2.0B -11.10 4.20 -54.84% 0.00% 16.56
Viridian 1.7B -7.18 5.35 -65.88% 0.00% 4.48
AbCellera Biologics 1.7B -11.23 1.69 -15.64% 100.00% 14.11

Financial data is updated regularly. All figures are in the company's reporting currency.